Laura Clague - Jan 10, 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role: Chief Financial Officer
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol: TVTX
Transactions as of: Jan 10, 2022
Transactions value $: -$205,500
Form type: 4
Date filed: 1/12/2022, 03:05 PM
Previous filing: Aug 17, 2021
Next filing: Jan 26, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TVTX	Common Stock	Award	$0	+7.5K	+23.95%	$0.00	38.8K	Jan 10, 2022	Direct	F1
transaction	TVTX	Common Stock	Sale	-$206K	-7.5K	-19.32%	$27.40	31.3K	Jan 11, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.
F2	The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Content

On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.

The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.